You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
Hepatitis B and C are among the most common viral infections in the world. At least 263 million worldwide in 2017 – are carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2
95% of people living with viral
hepatitis do not know.
In 2016, the World Health Assembly adopted WHO’s first
“Global Health Sector Strategy on viral hepatitis,”
with elimination as its overarching vision.
Sign up to receive regular updates about the Global Access Program.
A world where viral hepatitis transmission is halted
and everyone living with viral hepatitis has access to
safe, affordable and effective prevention, care and
treatment services.
GOAL
Eliminate viral hepatitis as a major public health
threat by 2030.
TARGETS
Between 6 and 10 million infections are
reduced to less than 1 million by 2030;
1.4 million deaths reduced to less than 500 000 by 2030.
Global Vision
A world where viral hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and effective prevention, care and treatment services
Goal
Eliminate viral hepatitis as a major public health threat by 2030
72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds
Roche committed to the elimination of hepatitis
To advance global efforts and eliminate viral hepatitis, Roche is committed
to this motivational program underscoring our ongoing efforts to provide
life-saving diagnostics, and supports governments aiming to cure people
of hepatitis.
Roche is a leader in viral load testing and is dedicated to enabling
improved patient management by delivering innovative, high-quality
diagnostic solutions where they are needed most.
* In development
Additional Global Access Program Hepatitis Information
